{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-030623","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.081918+00:00","generated_at":"2026-06-04T01:42:37.991766+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protara raises ~$45M in private placement; reports positive TARA-002 data and FDA alignment for IV Choline Chloride","bullets":["Private placement: gross proceeds ~$45M from 9.14M shares and 1.7M pre-funded warrants at $4.15; common warrants exercisable at $5.25.","FDA alignment on registrational path for IV Choline Chloride in PN patients; Phase 2b/3 THRIVE-3 to start in 1H 2025.","TARA-002 three-month CR 38% (6/16) in NMIBC; 63% in CIS-only; 43% in BCG-Unresponsive/Experienced; no Grade 3+ treatment-related AEs.","ADVANCED-2 Phase 2 trial adds 80 KE dose cohort and systemic priming; six-month data expected 2H 2024; plans TARA-002 + pembrolizumab combo."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-030623","json":"https://secwatch.observer/filing/0001213900-24-030623.json","markdown":"https://secwatch.observer/filing/0001213900-24-030623.md","text":"https://secwatch.observer/filing/0001213900-24-030623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/0001213900-24-030623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/ea0203128-8k_protar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:42:37.991766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3360232f69db4ca2e231eb3dd0fdc6cd89106f40","claim":"Protara Therapeutics, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-04-05).","evidence_excerpt":"In connection with the Private Placement, the Company also entered into a registration rights agreement, dated April 5, 2024 (the “Registration Rights Agreement”), with the Purchasers that requires, among other things, the Company to file a resale registration statement with the Securities and Exchange Commission (the “SEC”) within 30 days after the Closing to register the resale of the Shares and the shares of Common Stock underlying each of the Pre-Funded Warrants and the Common Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/0001213900-24-030623-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Purchasers"},{"label":"Effective","value":"2024-04-05"}],"fact_type":"material_agreement"},{"claim_id":"704090345278aaa2390d350eb22730a3ed44195d","claim":"Protara Therapeutics, Inc. entered into Subscription Agreement with certain purchasers (effective 2024-04-05).","evidence_excerpt":"On April 5, 2024, Protara Therapeutics, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with certain purchasers (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers, in a private placement (the “Private Placement”), an aggregate of 9,143,380 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) and, for certain purchasers, pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 1,700,000 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/0001213900-24-030623-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Effective","value":"2024-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}